210 related articles for article (PubMed ID: 31775675)
1. Dual time point
Yamagishi Y; Koiwai T; Yamasaki T; Einama T; Fukumura M; Hiratsuka M; Kono T; Hayashi K; Ishida J; Ueno H; Tsuda H
BMC Cancer; 2019 Nov; 19(1):1146. PubMed ID: 31775675
[TBL] [Abstract][Full Text] [Related]
2. Clinical Impact of Dual Time Point
Einama T; Yamagishi Y; Takihata Y; Konno F; Kobayashi K; Yonamine N; Fujinuma I; Tsunenari T; Kouzu K; Nakazawa A; Iwasaki T; Shinto E; Ishida J; Ueno H; Kishi Y
Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35954351
[TBL] [Abstract][Full Text] [Related]
3. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
4. Implications of standardized uptake value measurements of the primary lesions in proven cases of breast carcinoma with different degree of disease burden at diagnosis: does 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography predict tumor biology?
Basu S; Mavi A; Cermik T; Houseni M; Alavi A
Mol Imaging Biol; 2008; 10(1):62-6. PubMed ID: 18000713
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of Dmax and %ΔSUVmax of
Dang J; Peng X; Wu P; Yao Y; Tan X; Ye Z; Jiang X; Jiang X; Liu Y; Chen S; Cheng Z
BMC Med Imaging; 2023 Oct; 23(1):173. PubMed ID: 37907837
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of the standardized uptake value maximum change calculated by dual-time-point (18)F-fluorodeoxyglucose positron emission tomography imaging in patients with advanced non-small-cell lung cancer.
Jin F; Zhu H; Fu Z; Kong L; Yu J
Onco Targets Ther; 2016; 9():2993-9. PubMed ID: 27284249
[TBL] [Abstract][Full Text] [Related]
7. Dual time point FDG-PET/CT imaging... Potential tool for diagnosis of breast cancer.
Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E
Clin Radiol; 2008 Nov; 63(11):1213-27. PubMed ID: 18929039
[TBL] [Abstract][Full Text] [Related]
8. Utility of
Yamagishi Y; Yamasaki T; Ishida J; Moriya T; Einama T; Koiwai T; Fukumura-Koga M; Kono T; Hayashi K; Ueno H; Yamamoto J; Tsuda H
Ann Surg Oncol; 2020 Aug; 27(8):2698-2710. PubMed ID: 32124121
[TBL] [Abstract][Full Text] [Related]
9. Prediction of Clinical Molecular Typing of Breast Invasive Ductal Carcinoma Using
Zhang J; Liu Y; Fan H; Wang W; Shao W; Cao G; Shi X
Acad Radiol; 2023 Sep; 30 Suppl 2():S82-S92. PubMed ID: 36624021
[TBL] [Abstract][Full Text] [Related]
10. Identification of Axillary Lymph Node Metastasis in Patients With Breast Cancer Using Dual-Phase FDG PET/CT.
Sasada S; Masumoto N; Kimura Y; Kajitani K; Emi A; Kadoya T; Okada M
AJR Am J Roentgenol; 2019 Nov; 213(5):1129-1135. PubMed ID: 31339353
[No Abstract] [Full Text] [Related]
11. Prognostic relevance of ¹⁸F-FDG PET uptake in patients with locally advanced, extremity soft tissue sarcomas undergoing neoadjuvant isolated limb perfusion with TNF-α and melphalan.
Andreou D; Boldt H; Pink D; Jobke B; Werner M; Schuler M; Reichardt P; Tunn PU
Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1076-83. PubMed ID: 24519553
[TBL] [Abstract][Full Text] [Related]
12. The maximum standardized uptake value increment calculated by dual-time-point
Yonezawa N; Minamikawa T; Kitajima K; Takahashi Y; Sasaki R; Nibu KI; Komori T
Nagoya J Med Sci; 2017 Feb; 79(2):189-198. PubMed ID: 28626254
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of Percentage Change in Metabolic Parameters as Measured by Dual-Time Point
Yoo J; Yoon HJ; Kim BS
J Womens Health (Larchmt); 2017 Oct; 26(10):1131-1137. PubMed ID: 28498790
[TBL] [Abstract][Full Text] [Related]
14. FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results.
Buchbender C; Kuemmel S; Hoffmann O; Stahl AR; Kimmig R; Otterbach F; Ladd S; Koeninger A; Forsting M; Bockisch A; Antoch G; Heusner TA
Acta Radiol; 2012 Jul; 53(6):628-36. PubMed ID: 22761341
[TBL] [Abstract][Full Text] [Related]
15. Percentage change of primary tumor on 18F-FDG PET/CT as a prognostic factor for invasive ductal breast cancer with axillary lymph node metastasis: Comparison with MRI.
Yoo J; Kim BS; Chung J; Yoon HJ
Medicine (Baltimore); 2017 Aug; 96(31):e7657. PubMed ID: 28767583
[TBL] [Abstract][Full Text] [Related]
16. [Values of Different Evaluation Criteria of Interim
Zhu LT; Cen XN; Ou JP; Qiu ZX; Wang LH; Liu W; Wang WS; Dong YJ; Liang ZY; Wang MJ; Xu WL; Sun YH; Wang Q; Yin Y; Ren HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):431-437. PubMed ID: 28446288
[TBL] [Abstract][Full Text] [Related]
17. Utility of (18)F FDG-PET/CT for predicting prognosis of luminal-type breast cancer.
Aogi K; Kadoya T; Sugawara Y; Kiyoto S; Shigematsu H; Masumoto N; Okada M
Breast Cancer Res Treat; 2015 Feb; 150(1):209-17. PubMed ID: 25697596
[TBL] [Abstract][Full Text] [Related]
18. Dual-phase FDG PET/CT for predicting prognosis in operable breast cancer.
Ikejiri H; Sasada S; Emi A; Masumoto N; Kadoya T; Okada M
Breast; 2022 Oct; 65():98-103. PubMed ID: 35921799
[TBL] [Abstract][Full Text] [Related]
19. Prognostic analysis of interim
Yuan L; Kreissl MC; Su L; Wu Z; Hacker M; Liu J; Zhang X; Bo Y; Zhang H; Li X; Li S
Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):478-488. PubMed ID: 30382301
[TBL] [Abstract][Full Text] [Related]
20. The Predictive Value of Early Changes in
He M; Liu C; Shi Q; Sun Y; Zhang Y; Xu X; Yuan H; Zhang Y; Liu Y; Liu G; Di G; Yang Z; Wang Z; Shao Z
Oncologist; 2020 Nov; 25(11):927-936. PubMed ID: 32272493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
